Stay updated on SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.

Latest updates to the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check35 days agoNo Change Detected
- Check42 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check49 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check64 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check71 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.SummaryDifference0.2%
- Check100 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
Stay in the know with updates to SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.